ImmunityBio, Inc. Profile Avatar - Palmy Investing

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulato…

Biotechnology
US, San Diego [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

ImmunityBio, Inc. can't present it's latest revenue by geo. area

Revenue By Geographic Areas

ImmunityBio, Inc. can't present it's latest revenue by geo. area

Historical Revenue By Segment

Last 3Y, in mil. USD

ImmunityBio, Inc. can't present revenue by segment

Historical Revenue By Geographic Area

Last 3Y, in mil. USD

ImmunityBio, Inc. can't present revenue by geo. area

End of IBRX's Analysis
CIK: 1326110 CUSIP: 45256X103 ISIN: US45256X1037 LEI: - UEI: -
Secondary Listings
IBRX has no secondary listings inside our databases.